Metabolomic approach to human brain spectroscopy identifies associations between clinical features and the frontal lobe metabolome in multiple sclerosis

NeuroImage

Volumn 82, Issue , 2013, Pages 586-594

  Vingara, Lisa K ^a   Yu, Hui Jing ^b   Wagshul, Mark E ^c   Serafin, Dana ^c   Christodoulou, Christopher ^c   Pelczer, István ^a   Krupp, Lauren B ^c   Maletić Savatić, Mirjana ^c  

^a PRINCETON UNIVERSITY   (United States)

^b St Francis Hospital The Heart Center   (United States)

^c STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Magnetic resonance spectroscopy (MRS); Metabolomics; Multivariate statistics; Relapsing remitting multiple sclerosis

Indexed keywords

ADULT; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DISABILITY; DISCRIMINANT ANALYSIS; FEMALE; FRONTAL LOBE; HUMAN; IN VIVO STUDY; MALE; METABOLOMICS; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL LEAST SQUARES REGRESSION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRESS;

(1)H-MRS; CONTROL WHITE MATTER, I.E., MRS OF WHITE MATTER FROM HEALTHY CONTROLS; CTWM; MAGNETIC RESONANCE SPECTROSCOPY; MAGNETIC RESONANCE SPECTROSCOPY (MRS); METABOLOMICS; MRS; MULTIVARIATE STATISTICS; NAWM; NELES; NORMAL-APPEARING WHITE MATTER, I.E., MRS FROM THE FRONTAL LOBE IN RRMS PATIENTS; PERIVENTRICULAR NON-ENHANCING LESIONS IN RRMS PATIENTS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; RELAPSING-REMITTING MULTIPLE SCLEROSIS; RRMS;

ADULT; FEMALE; FRONTAL LOBE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOME; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; YOUNG ADULT;

EID: 84880034564     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2013.05.125     Document Type: Article

References (57)

1. Arnold D.L., Riess G.T., Matthews P.M., Francis G.S., Collins D.L., Wolfson C., Antel J.P. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann. Neurol. 1994, 36:76-82.
2. Bakshi R., Thompson A.J., Rocca M.A., Pelletier D., Dousset V., Barkhof F., Inglese M., Guttmann C.R.G., Horsfield M.A., Filippi M. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol. 2008, 7:615-625.
3. Barker M., Rayens W. Partial least squares for discrimination. J. Chemom. 2003, 17(3):166-173.
4. Brindle J.T., Antti H., Holmes E., Tranter G., Nicholson J.K., Bethell H.W.L., Clarke S., Schofield P.M., McKilligin E., Mosedale D.E., et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat. Med. 2002, 8(1439-1445):1439.
5. Caramanos Z., Narayanan S., Arnold D.L. 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain 2005, 128(11):2483-2506.
6. Chang L., Ernst T., Poland R.E., Jenden D.J. In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sci. 1996, 58(22):2049-2056.
7. Chang L., Jiang C.S., Ernst T. Effects of age and sex on brain glutamate and other metabolites. Magn. Reson. Imaging 2009, 27(1):142-145.
8. Chard D., Griffin C.M., McLean M.A., Kapeller P., Kapoor R., Thompson A.J., Miller D.H. Brain metabolites changes in cortical grey and normal appearing white matter in clinically early relapsing remitting multiple sclerosis. Brain 2002, 125:2342-2352.
9. Christodoulou C., Krupp L.B., Liang Z., Huang W., Melville P., Roque C., Scherl W.F., Morgan T., MacAllister W.S., Li L., et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. Neurology 2003, 60(11):1793-1798.
10. Craig A., Cloarec O., Holmes E., Nicholson J.K., Lindon J.C. Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal. Chem. 2006, 78(7):2262-2267.
11. Davies S.E., Newcombe J., Williams S.R., McDonald W.I., Clark J.B. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J. Neurochem. 1995, 64(2):742-748.
12. De Stefano N., Filippi M. MR spectroscopy in multiple sclerosis. J. Neuroimaging 2007, 17(Suppl. 1):31S-35S.
13. De Stefano N., Matthews P.M., Fu L., Narayanan S., Stanley J., Francis G.S., Antel J.P., Arnold D.L. Axonal damage correlates with disability in patients with relapsing remitting multiple sclerosis. Brain 1998, 121:1469-1477.
14. De Stefano N., Narayanan S., Francis G.S., Arnaoutelis R., Tartaglia M.C., Antel J.P. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch. Neurol. 2001, 58:65-70.
15. Dehmeshki J., Ruto A.C., Arridge S., Silver N.C., Miller D.H., Tofts P.S. Analysis of MTR histograms in multiple sclerosis using principal components and multiple discriminant analysis. Magn. Reson. Med. 2001, 46(3):600-609.
16. Fazekas F., Barkhof F., Filippi M., Grossman R.I., Li D.K.B., McDonald W.I., McFarland H.F., Paty D.W., Simon J.H., Wolinsky J.S., et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 1999, 53(3):448-456.
17. Filippi M., Tortorella C., Bozzali M. Normal-appearing white matter changes in multiple sclerosis: the contribution of magnetic resonance techniques. Mult. Scler. 1999, 5(4):273-282.
18. Frahm J., Bruhn H., Gyngell M.L., Merboldt K.D., Hänicke W., Sauter R. Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn. Reson. Med. 1989, 9(1):79-93.
19. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354(9):942-955.
20. Fukuzako H., Hashiguchi T., Sakamoto Y., Okamura H., Doi W., Takenouchi K., Takigawa M. Metabolite changes with age measured by proton magnetic resonance spectroscopy in normal subjects. Psychiatry Clin. Neurosci. 1997, 51(4):261-263.
21. Galanaud D., Nicoli F., Chinot O., Confort-Gouny S., Figarella-Branger D., Roche P., Fuentès S., Le Fur Y., Ranjeva J., Cozzone P.J. Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy. Magn. Reson. Med. 2006, 55(6):1236-1245.
22. Govindaraju V., Young K., Maudsley A.A. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000, 13(3):129-153.
23. Griffin J.L. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr. Opin. Chem. Biol. 2003, 7(5):648-654.
24. Gronwell D. Paced auditory serial addition task: a measure of recovery from concussion. Percept. Mot. Skills 1977, 44:367-373.
25. Hassan-Smith G., Wallace G.R., Douglas M.R., Sinclair A.J. The role of metabolomics in neurological disease. J. Neuroimmunol. 2012, 248:48-52.
26. Hobson C.J., Kamen J., Szostek J., Nethercut C.M., Tiedmann J.W., Wojnarowicz S. Stressful life events: a revision and update of the social readjustment rating scale. Int. J. Stress. Manag. 1998, 5(1):1-23.
27. Holmes T.H., Rahe R.H. The social readjustment rating scale. J. Psychosom. Res. 1967, 11(2):213-218.
28. Inglese M., Ge Y. Quantitative MRI: hidden age-related changes in brain tissue. Top. Magn. Reson. Imaging 2004, 15(6):355-363.
29. Kadota T., Horinouchi T., Kuroda C. Development and aging of the cerebrum: assessment with proton MR spectroscopy. Am. J. Neuroradiol. 2001, 22(1):128-135.
30. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 1989, 46(10):1121-1123.
31. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an extended disability status scale (EDSS). Neurology 1983, 33:1444-1452.
32. Kurtzke J.F., Wallin M.T. Epidemiology. Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation 2000, 49-71. Demos Medical Publishing, Inc., New York. J.S. Burks, K.P. Johnson (Eds.).
33. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., Brück W., Rauschka H., Bergmann M., Schmidbauer M., Parisi J.E., Lassmann H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128(11):2705-2712.
34. Leary S.M., Brex P.A., MacManus D.G., Parker G.J.M., Barker G.J., Miller D.H., Thompson A.J. A 1H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis. Magn. Reson. Imaging 2000, 18:455-459.
35. Lindon J.C., Nicholson J.K. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu. Rev. Anal. Chem. 2008, 1(1):45-69.
36. Mainero C., De Stefano N., Iannucci G., Sormani M.P., Guidi L., Federico A., Bartolozzi M.L., Comi G., Filippi M. Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology 2001, 56:1331-1334.
37. Mathiesen H.K., Jonsson A., Tscherning T., Hanson L.G., Andresen J., Blinkenberg M., Paulson O.B., Sorensen P.S. Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch. Neurol. 2006, 63(4):533-536.
38. Mohr D.C., Goodkin D.E., Bacchetti P., Boudewyn A.C., Huang L., Marrietta P., Cheuk W., Dee B. Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology 2000, 55(1):55-61.
39. Narayana P.A. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J. Neuroimaging 2005, 15:46S-57S.
40. Nici J. A compendium of neuropsychological tests, 2nd ed. Arch. Neurol. 2000, 57(2):278.
41. Odunsi K., Wollman R.M., Ambrosone C.B., Hutson A., McCann S.E., Tammela J., Geisler J.P., Miller G., Sellers T., Cliby W., et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int. J. Cancer 2005, 113(5):782-788.
42. Parmenter B.A., Weinstock-Guttman B., Garg N., Munschauer F., Benedict R.H. Screening for cognitive impairment in multiple sclerosis using the symbol digit modalities test. Mult. Scler. 2007, 13(1):52-57.
43. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69(2):292-302.
44. Poullet J., Sima D.M., Van Huffel S. MRS signal quantitation: a review of time- and frequency-domain methods. J. Magn. Reson. 2008, 195(2):134-144.
45. Preul M.C., Caramanos Z., Collins D.L., Villemure J., Leblanc R., Olivier A., Pokrupa R., Arnold D.L. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat. Med. 1996, 2(3):323-325.
46. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993, 30(6):672-679.
47. Rajalahti T., Kroksveen A.C., Arneberg R., Berven F.S., Vedeler C.A., Myhr K., Kvalheim O.M. A multivariate approach to reveal biomarker signatures for disease classification: application to mass spectral profiles of cerebrospinal fluid from patients with multiple sclerosis. J. Proteome Res. 2010, 9(7):3608-3620.
48. Ruiz-Pena J., Pinero P., Sellers G., Argente J., Casado A., Foronda J., Ucles A., Izquierdo G. Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy. BMC Neurol. 2004, 4(1):8.
49. Sajja B.R., Wolinsky J.S., Narayana P.A. Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin. N. Am. 2009, 19(1):45-58.
50. Schuff N., Ezekiel F., Gamst A.C., Amend D.L., Capizzano A.A., Maudsley A.A., Weiner M.W. Region and tissue differences of metabolites in normally aged brain using multislice 1H magnetic resonance spectroscopic imaging. Magn. Reson. Med. 2001, 45(5):899-907.
51. Smolinska A., Blanchet L., Buydens L.M.C., Wijmenga S.S. NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review. Anal. Chim. Acta 2012, 750:82-97.
52. Srinivasan R., Sailasuta N., Hurd R., Nelson S., Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3T. Brain May 2005, 128(5):1016-1025.
53. Trygg J., Wold S. Orthogonal projections to latent structures (O-PLS). J. Chemom. 2002, 16(3):119-128.
54. Vernooij M.W., de Groot M., van der Lugt A., Ikram M.A., Krestin G.P., Hofman A., Niessen W.J., Breteler M.M.B. White matter atrophy and lesion formation explain the loss of structural integrity of white matter in aging. NeuroImage 2008, 43(3):470-477.
55. Weygandt M., Hackmack K., Pfüller C., Bellmann-Strobl J., Paul F., Zipp F., Haynes J. MRI pattern recognition in multiple sclerosis normal-appearing brain areas. PLoS One 2011, 6(6):e21138.
56. Williams H.R.T., Cox I.J., Walker D.G., North B.V., Patel V.M., Marshall S.E., Jewell D.P., Ghosh S., Thomas H.J.W., Teare J.P., et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am. J. Gastroenterol. 2009, 104(6):1435-1444.
57. Zhou J., Xu B., Huang J., Jia X., Xue J., Shi X., Xiao L., Li W. 1H NMR-based metabonomic and pattern recognition analysis for detection of oral squamous cell carcinoma. Clin. Chim. Acta 2009, 401(1-2):8-13.